Evidence map›Paper›PMID 32667461›Full record

ArticleMemorias do Instituto Oswaldo Cruz2020

SARS-CoV-2 diagnostic diary: from rumors to the first case. Early reports of molecular tests from the military research and diagnostic institute of Rio de Janeiro.

Marcio da Costa Cipitelli, Elizabeth Valentin, Nadia Vaez Gonçalves da Cruz, Tatiana Ls Nogueira, Elaine Cristina Amaro de Melo, Rebeca Araujo da Silva, Marcelo M Serra, André L Meriano, Alberto Ml Colares, Marcos Dornelas-Ribeiro and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Memorias do Instituto Oswaldo Cruz, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Are SARS-CoV-2 reinfection and Covid-19 recurrence possible? a case report from Brazil.Revista da Sociedade Brasileira de Medicina Tropical · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marcio da Costa CipitelliLaboratório de Biologia Molecular, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.
Elizabeth ValentinLaboratório de Biodefesa, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.
Nadia Vaez Gonçalves da CruzLaboratório de Biodefesa, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.
Tatiana Ls NogueiraLaboratório de Genética, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.
Elaine Cristina Amaro de MeloLaboratório de Biologia Molecular, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.
Rebeca Araujo da SilvaLaboratório de Biologia Molecular, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.
Marcelo M SerraLaboratório de Biodefesa, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.
André L MerianoLaboratório de Biologia Molecular, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.
Alberto Ml ColaresLaboratório de Biodefesa, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.
Marcos Dornelas-RibeiroLaboratório de Biologia Molecular, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.
Caleb Gm SantosLaboratório de Biologia Molecular, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Corona virus disease (COVID-19) presents a serious threat to global health. A historical timeline of early molecular diagnostics from government alert (January 22) (D) was presented. After in silico analysis, Brazilian Army Institute of Biology (IBEx-RJ) tested samples in house using real-time reverse transcriptase polymerase chain reaction (RT-PCR) (fast mode) based on Centers for Disease Control and Prevention (CDC) recommendations. First cases from Brazil, Rio de Janeiro, IBEx, and diagnosis team were reported in D36, D44, D66, and D74 respectively. Therefore, after 1300 tests, we recommend N1/N2 primer sets (CDC) for preliminary and Charité protocol confirmation in case of positive results. Moreover, every professional should be tested before starting work, in addition to weekly tests for everyone involved.

Indexed as

BetacoronavirusBrazilCoronavirus InfectionsCOVID-19HumansMilitary FacilitiesPandemicsPneumonia, ViralReverse Transcriptase Polymerase Chain ReactionSARS-CoV-2

Identifiers

PMID32667461
PMCPMC7357545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.